Cargando…

Prevalence of diabetic nephropathy in Type 2 Diabetes Mellitus in rural communities of Guanajuato, Mexico. Effect after 6 months of Telmisartan treatment

OBJECTIVE: To determine the prevalence of Diabetic Nephropathy (DN) in patients with type 2 Diabetes Mellitus (T2DM) with over 5 years of evolution in rural communities of Guanajuato, Mexico, and evaluate the effects of an ARB treatment over 6 months in patients with DN. MATERIALS AND METHODS: Patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Zenteno-Castillo, Priscyla, Muñoz-López, Daniela Beatriz, Merino-Reyes, Benjamín, Vega-Sánchez, Ángel, Preciado-Puga, Monica, González-Yebra, Ana Lilia, Kornhauser, Carlos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685013/
https://www.ncbi.nlm.nih.gov/pubmed/29159116
http://dx.doi.org/10.1016/j.jcte.2015.08.001
_version_ 1783278572170903552
author Zenteno-Castillo, Priscyla
Muñoz-López, Daniela Beatriz
Merino-Reyes, Benjamín
Vega-Sánchez, Ángel
Preciado-Puga, Monica
González-Yebra, Ana Lilia
Kornhauser, Carlos
author_facet Zenteno-Castillo, Priscyla
Muñoz-López, Daniela Beatriz
Merino-Reyes, Benjamín
Vega-Sánchez, Ángel
Preciado-Puga, Monica
González-Yebra, Ana Lilia
Kornhauser, Carlos
author_sort Zenteno-Castillo, Priscyla
collection PubMed
description OBJECTIVE: To determine the prevalence of Diabetic Nephropathy (DN) in patients with type 2 Diabetes Mellitus (T2DM) with over 5 years of evolution in rural communities of Guanajuato, Mexico, and evaluate the effects of an ARB treatment over 6 months in patients with DN. MATERIALS AND METHODS: Patients of both sexes, 38–86 years, T2DM over 5 years of evolution and diagnosed with arterial hypertension (HT) after T2DM incidence. Monthly determination of microalbuminuria (MA), lipids, glucose, serum creatinine, and glycated hemoglobin (HbA1c). Estimated glomerular filtration rate (eGFR) by the Modification of Diet in Renal Disease (MDRD) formula. A dose of 80 mg of Telmisartan was administered daily over 6 months. RESULTS: The total adult population of two rural communities (3609 subjects) was studied, 335 subjects had T2DM, among them 80 (with a prevalence of 24%) had DN and HT. Sixty-seven patients received Telmisartan, and showed significant improvement in all parameters studied. CONCLUSIONS: A higher prevalence of DN than that reported in the Mexican National Health Survey (ENSANUT) was found. Further research is required in a larger population sample in order to confirm the results of Telmisartan treatment.
format Online
Article
Text
id pubmed-5685013
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-56850132017-11-20 Prevalence of diabetic nephropathy in Type 2 Diabetes Mellitus in rural communities of Guanajuato, Mexico. Effect after 6 months of Telmisartan treatment Zenteno-Castillo, Priscyla Muñoz-López, Daniela Beatriz Merino-Reyes, Benjamín Vega-Sánchez, Ángel Preciado-Puga, Monica González-Yebra, Ana Lilia Kornhauser, Carlos J Clin Transl Endocrinol Research Paper OBJECTIVE: To determine the prevalence of Diabetic Nephropathy (DN) in patients with type 2 Diabetes Mellitus (T2DM) with over 5 years of evolution in rural communities of Guanajuato, Mexico, and evaluate the effects of an ARB treatment over 6 months in patients with DN. MATERIALS AND METHODS: Patients of both sexes, 38–86 years, T2DM over 5 years of evolution and diagnosed with arterial hypertension (HT) after T2DM incidence. Monthly determination of microalbuminuria (MA), lipids, glucose, serum creatinine, and glycated hemoglobin (HbA1c). Estimated glomerular filtration rate (eGFR) by the Modification of Diet in Renal Disease (MDRD) formula. A dose of 80 mg of Telmisartan was administered daily over 6 months. RESULTS: The total adult population of two rural communities (3609 subjects) was studied, 335 subjects had T2DM, among them 80 (with a prevalence of 24%) had DN and HT. Sixty-seven patients received Telmisartan, and showed significant improvement in all parameters studied. CONCLUSIONS: A higher prevalence of DN than that reported in the Mexican National Health Survey (ENSANUT) was found. Further research is required in a larger population sample in order to confirm the results of Telmisartan treatment. Elsevier 2015-08-18 /pmc/articles/PMC5685013/ /pubmed/29159116 http://dx.doi.org/10.1016/j.jcte.2015.08.001 Text en © 2015 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Paper
Zenteno-Castillo, Priscyla
Muñoz-López, Daniela Beatriz
Merino-Reyes, Benjamín
Vega-Sánchez, Ángel
Preciado-Puga, Monica
González-Yebra, Ana Lilia
Kornhauser, Carlos
Prevalence of diabetic nephropathy in Type 2 Diabetes Mellitus in rural communities of Guanajuato, Mexico. Effect after 6 months of Telmisartan treatment
title Prevalence of diabetic nephropathy in Type 2 Diabetes Mellitus in rural communities of Guanajuato, Mexico. Effect after 6 months of Telmisartan treatment
title_full Prevalence of diabetic nephropathy in Type 2 Diabetes Mellitus in rural communities of Guanajuato, Mexico. Effect after 6 months of Telmisartan treatment
title_fullStr Prevalence of diabetic nephropathy in Type 2 Diabetes Mellitus in rural communities of Guanajuato, Mexico. Effect after 6 months of Telmisartan treatment
title_full_unstemmed Prevalence of diabetic nephropathy in Type 2 Diabetes Mellitus in rural communities of Guanajuato, Mexico. Effect after 6 months of Telmisartan treatment
title_short Prevalence of diabetic nephropathy in Type 2 Diabetes Mellitus in rural communities of Guanajuato, Mexico. Effect after 6 months of Telmisartan treatment
title_sort prevalence of diabetic nephropathy in type 2 diabetes mellitus in rural communities of guanajuato, mexico. effect after 6 months of telmisartan treatment
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685013/
https://www.ncbi.nlm.nih.gov/pubmed/29159116
http://dx.doi.org/10.1016/j.jcte.2015.08.001
work_keys_str_mv AT zentenocastillopriscyla prevalenceofdiabeticnephropathyintype2diabetesmellitusinruralcommunitiesofguanajuatomexicoeffectafter6monthsoftelmisartantreatment
AT munozlopezdanielabeatriz prevalenceofdiabeticnephropathyintype2diabetesmellitusinruralcommunitiesofguanajuatomexicoeffectafter6monthsoftelmisartantreatment
AT merinoreyesbenjamin prevalenceofdiabeticnephropathyintype2diabetesmellitusinruralcommunitiesofguanajuatomexicoeffectafter6monthsoftelmisartantreatment
AT vegasanchezangel prevalenceofdiabeticnephropathyintype2diabetesmellitusinruralcommunitiesofguanajuatomexicoeffectafter6monthsoftelmisartantreatment
AT preciadopugamonica prevalenceofdiabeticnephropathyintype2diabetesmellitusinruralcommunitiesofguanajuatomexicoeffectafter6monthsoftelmisartantreatment
AT gonzalezyebraanalilia prevalenceofdiabeticnephropathyintype2diabetesmellitusinruralcommunitiesofguanajuatomexicoeffectafter6monthsoftelmisartantreatment
AT kornhausercarlos prevalenceofdiabeticnephropathyintype2diabetesmellitusinruralcommunitiesofguanajuatomexicoeffectafter6monthsoftelmisartantreatment